No full-text available
To read the full-text of this research,
you can request a copy directly from the authors.
Microimmunotherapeutic administration of cytokines improve the clinical symptoms in EAE an animal model of multiple sclerosis
... The released cytokines from immune cells alter the milieu and lead to overexpression of mediatory factors such as matrix metalloproteinases (MMPs) that culminate in blood-brain barrier (BBB) impairment and subsequent infiltration of various immune cells. Demyelination and relapse of multiple sclerosis (MS) is an inflammatoryinduced ailment of the CNS, but degeneration of the soma and axon is independent of inflammation and progressed by accumulative disabilities resulting from abnormalities in the mitochondriae (Camps et al., 2016). The situation eventually results in different neurological, cognitive, and emotional disabilities in the final stages (Ayache and Chalah, 2016;Alizadeh-Ghodsi et al., 2018). ...
Stem cell therapy has indicated a promising treatment capacity for tissue regeneration. Multiple sclerosis is an autoimmune-based chronic disease, in which the myelin sheath of the central nervous system is destructed. Scientists have not discovered any cure for multiple sclerosis, and most of the treatments are rather palliative. The pursuit of a versatile treatment option, therefore, seems essential. The immunoregulatory and non-chronic rejection characteristics of mesenchymal stem cells, as well as their homing properties, recommend them as a prospective treatment option for multiple sclerosis. Different sources of mesenchymal stem cells have distinct characteristics and functional properties; in this regard, choosing the most suitable cell therapy approach seems to be challenging. In this review, we will discuss umbilical cord/blood-derived mesenchymal stem cells, their identified exclusive properties compared to another adult mesenchymal stem cells, and the expectations of their potential roles in the treatment of multiple sclerosis.
Die Mikroimmuntherapie ist ein therapeutischer Ansatz zur Regulierung des Immunsystems, bei dem immunregulierende Wirkstoffe wie Zytokine und Nukleinsäuren in niedrigen Dosierungen (Mikrodosen) zum Einsatz kommen. Durch die Mikroimmuntherapie soll u. a. das Immunsystem in der Auseinandersetzung mit Krankheitserregern unterstützt, eine spezifisch modulierende Wirkung auf akute und chronische Entzündungen und deren Folgewirkungen erzielt und die allergische Reaktion eingedämmt werden.
ResearchGate has not been able to resolve any references for this publication.